Georgiamune
PrivateLast Round
Series B
Sep 18, 2026
Est. Valuation
$389M
Total Funding Raised
$172.19M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Georgiamune is a biotechnology company that develops immunotherapies aimed at reprogramming immune signaling pathways to treat cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Georgiamune Comparables
Compare Georgiamune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immune-Onc Therapeutics | 85% | |
| iOmx Therapeutics | 84% | |
| OncoC4, Inc. | 84% |
Georgiamune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 18, 2026 | ||||
| Series B | Aug 17, 2026 | ||||
| Series A | Aug 9, 2023 |
Georgiamune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Prevail Strategies | Series B |
| Parker Institute for Cancer Immunotherapy | Series A |
| Catalio Capital Management | Series B, Series A |
| General Catalyst | Series B, Series A |
| Mubadala Capital | Series B, Series A |
| Alexandria Venture Investments | Series B, Series A |
| CJNV BioVenture | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
$93M round led by Mubadala Capital and Prevail Strategies.
- Aug 17, 2026
$93M round completed.
Georgiamune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Georgiamune's valuation, stock price, and market status.
Is Georgiamune a public or private company?
Georgiamune is a private company.
What is the current stock price of Georgiamune?
Georgiamune is a private company with no public stock price. No recent secondary market data is available.
How much is Georgiamune worth (valuation)?
Valuation information for Georgiamune is not publicly available.
Can I buy Georgiamune stock?
Georgiamune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Georgiamune's last funding round?
Georgiamune's most recent funding round was Series A on August 9, 2023.
Who are the main investors in Georgiamune?
Key investors in Georgiamune include Parker Institute for Cancer Immunotherapy, General Catalyst.
Will Georgiamune IPO soon?
No public IPO plans have been announced for Georgiamune.
How can I track Georgiamune secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Georgiamune's secondary market activity and sign up for updates.